The global sales of canine cancer screening are estimated to be worth USD 1,397.0 million in 2024 and anticipated to reach a value of USD 2,087.9 million by 2034. Sales are projected to rise at a CAGR of 4.1% over the forecast period between 2024 and 2034. The revenue generated by canine cancer screening in 2023 was USD 1,342.0 million.
The genetic predisposition of dog breeds to certain types of cancers brings about critical drivers of the canine cancer screening market. Such a phenomenon underlines not only the importance of genetic factors in the susceptibility of cancer but also the already increasing demand for adequate screening and early detection tailored to such predispositions.
There are inherited mutations in tumor suppressor genes that predispose certain breeds of dogs to specific kinds of cancer. Such would include Rottweilers, who are more inclined to develop osteosarcoma; German Shepherds, who are more susceptible to lymphoma; and Golden Retrievers, who show predispositions for hemangiosarcoma.
The consequence of such limited genetic diversity within the breeds can lead to the concentration of harmful variants, hence making the finding of breed-specific cancer risks with genetic and genome-wide association studies much easier.
Global Canine Cancer Screening Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 1,342.0 million |
| Estimated Size, 2024 | USD 1,397.0 million |
| Projected Size, 2034 | USD 2,087.9 million |
| Value-based CAGR (2024 to 2034) | 4.1% |
With a better understanding of the breed-inclined cancer conditions, the owners are very aware to become more proactive about the health status of their pets. The increased awareness means more demand for genetic testing and screening services as people seek to take precautionary measures for their pets. This could go further by the use of educational campaigns and recommendations by veterinaries for regular screenings as part of routine veterinary care.
Continual improvement in genetic testing technologies and relative ease of identification of cancer predispositions in some breeds will further facilitate use of such tools. Testing for mutations within some of the key tumor suppressor genes-such as p53 and BHD-can be used to help owners understand their dog's risk of developing certain types of cancer. As these tests become more available and more reasonably priced, they are likely to fuel increased demand for screening services, especially among breeds with documented hereditary cancer predispositions.
An example could be Rottweilers: This breed has been suffering from most types of cancers, including osteosarcoma and hemangiosarcoma. It has been noted that the mutations in MET proto-oncogene are common in this breed; hence, it shows that there might be a genetic link for cancers in dogs. These cancers can be diagnosed by regular checkups.
These cancers can easily be detected through regular testing, which leads to better results regarding such diseases. One of the major growth factors in the canine cancer screening market is the genetic predisposition in certain breeds for specific types of cancers.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As Research Continues to Advance and These Technologies Become More Widely Available, hence the Canine Cancer Screening Witnessing Poised Growth.
The different advances in the field of veterinary diagnostics have enabled the development of better screening methodologies that would help in the early stages of detection and with more accuracy in canine cancers. It is expected that these innovative techniques will improve treatment outcomes and increase demand for screening services among pet owners.
Liquid biopsies, which test blood samples, have emerged as one of the most promising tests for cancer screening in dogs. These tests, such as OncoK9 by PetDx, measure cell-free DNA (cfDNA) and other biomarkers released by tumor cells into the bloodstream. By detecting these cancer-associated signals, liquid biopsy tests can identify the presence of cancer, even in the absence of visible symptoms or tumors. In some cases, the liquid biopsy tests offer cancerous-related signals that determine the presence of cancer in the absence of symptoms or even tumors.
Another considerable advantage of liquid biopsy is that it is noninvasive and easy to manage. Unlike traditional tissue biopsies, presupposing invasive methods of treatment, this biopsy can be conducted simply by drawing blood.
2024 Virginia Tech researchers have come up with a weird urinalysis method to detect the presence of cancer in canines by an easy and noninvasive test. The new technique utilizes Raman spectroscopy, which checks urine samples to trace a singular "fingerprint" of cancer generated by the display of specific molecules. In pilot studies, this test came out well by producing more than 90% accuracy in distinguishing between cancerous and healthy samples.
Improved diagnosis techniques for canine cancer screening have impacted the market in terms of increasing demand for its screening services, which in turn results in improved outcomes of treatment for the pets concerned.
The Rising Pet Adoption Rates Among Younger Generations Is Driving the Canine Cancer Screening Market.
A great driving force is due to trend of pet ownership, especially among younger generations. With more households embracing canine members into their families, a huge demand has been created for complete health services that involve the screening of cancer in these animal companions.
Millennial and Generation Z pet owners have emerged as the main driving forces for the growth in the pet market. As a matter of fact, in the 2022 APPA National Pet Owners Survey, millennials accounted for the highest percentage of dog owners at 33%, followed by Generation Z at 32%. This can be seen even more in the category of dog ownership, as the trend shows there is a great preference of the owners towards canine companionship.
The fondness for dogs among young animal owners is not confined to their companionship. To many millennials and Gen Z people, pets are part of the family. Such a mentality has led to increased interest in investment in preventive care, such as screening pets for cancer. Along with the rise in pet-owning households, health services relating to dogs expanded not only in type but also in number. Notably, younger generations are more than willing to seek higher-order vet care, including specialty treatments and diagnostic testing for their pets.
This has been the trend in cancer screening. It has been the notion of early detection that keeps getting better and, with the introduction of new innovative ways of screening, owners have been more attracted to these services for their canine companions. Liquid biopsy tests, urine-based screenings, and advanced diagnostic techniques have cropped up to feed the demand brought about by younger demographics.
Investments in Preventive Measures of Canine Health as Increased Spending Eventually Propelling the Market Growth
Prominent factor that positively impacts demand in the canine cancer screening market is the increase in veterinary service expenditure, which is continually rising because of the growing trend of pet ownership, especially among younger generations. Pet owners are investing in preventive health of their pets. According to APPA, total pet spending in 2022 averaged at around USD 136.8 billion, up from USD 123.6 billion in 2021.
The American Pet Products Association National Pet Owners Survey 2022 showed that pet parents spent an average of USD 1,643 on veterinary care for their dogs in 2021. This, too, is an amount that was noted in general amounts people have splurged on their pets in recent years.
The connection between pet owners and dogs has gradually increased due to pandemic, which is leading to increased spending on pet health. Many households adopted pets during the pandemic simultaneously the need for regular health check-ups and screenings becomes more important. This trend is expected to continue as pet ownership stabilizes at higher levels than pre-pandemic times.
The expansion of the canine cancer screening market has tremendous potential for growth, as spending on pet health is on the rise, thus guaranteeing better health conditions for the animals and a clearer conscience on the part of their owners.
Understanding The Potential Side Effects Is Essential for Making Informed Decisions About Canine Cancer Care
The side effects resulting from the different cancer treatments for dogs is the effective constraint for owners to have their necessary screenings and treatments. While therapies such as chemotherapy are effective treatments against a variety of malignancies, there are also adverse effects related to these treatments. An understanding of these side effects is crucial with pet owners considering options available in regard to canine cancer care. The possible side effects of chemotherapy include gastrointestinal toxicity, which can be manifested in several ways: vomit, diarrhea, and loss of appetite.
These are further associated with nausea and vomiting, possibly resulting from direct effects of the chemotherapy drugs on the gastrointestinal tract, stimulating its inflammation and irritation. For instance, drugs like cisplatin require treatment that will cause nausea and vomiting some time just after treatment, while others may cause post-treatment gastrointestinal complications a number of days from the time of treatment. Many of these side effects require additional veterinary treatment and intervention, including the prescription of anti-nausea medications and dietary changes.
The possibility of these side effects will sometimes discourage pet owners from pursuing such aggressive therapies. Quality-of-life concerns for their pets during and subsequent to treatment can be very distressing. Reports of extreme adverse reactions can prevent pet owners from pursuing traditional veterinary care due to fear of the foregoing possible negative outcomes associated with chemotherapy.
The various side effects of the different cancer therapies in dogs make many pet owners highly problematic when considering a choice of screening and treatment.
The global canine cancer screening industry recorded a CAGR of 4.1% during the historical period between 2018 and 2023. The growth of canine cancer screening industry was positive as it reached a value of USD 1,342.0 million in 2023 from USD 1,134.7 million in 2018.
In the past decade, canine cancer screening has seen remarkable growth, influenced by an upsurge in concern related to canine health issues and advancements made within the diagnostics of veterinary medicine. Conventional historical outlook shows that a limitation in diagnostic tools is usually characteristic of such markets; this influences lower survival rates because disease diagnosis and detection occur rather late.
However, this scenario changed dramatically with the advent of more advanced veterinary technologies that brought in new diagnostic methods involving higher degrees of sophistication into the market, such as advanced imaging and PCR-based tests.
The future outlook for canine cancer screening is promising, as the growth will be continued by the key influential factors. This is going to be added to with early detection by advancements in veterinary diagnostics, especially in genetic tests and biomarker identifications, leading to timely accurate diagnosis. Increased penetration of next generation sequencing and liquid biopsy technology is expected to further propel the market on account of its non-invasive and highly sensitive screening possibilities.
Principal Consultant
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 61.1% in global market. They invest heavily in technologies such as next-generation sequencing and advanced imaging techniques, ensuring they offer the most accurate and efficient screening solutions. Prominent companies in tier 1 include Nestle, Boehringer Ingelheim, Virbac, Beaphar., and Nutramax Laboratories, Inc.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 36.1% market share. They focus on specific types of cancer or particular diagnostic technologies, allowing them to build expertise and cater to specialized needs within the market.
They offer more affordable or value-oriented diagnostic tools compared to Tier 1 companies, making advanced cancer screening more accessible to a broader audience. Prominent companies in tier 2 include Nutri-Pet Research, Inc., Ceva and Canna Companion.
Finally, Tier 3 companies, such as FoodScience and NOW Foods. They specialize in specific products and cater to niche markets, adding diversity to the industry. Overall, while Tier 1 companies are the primary drivers of the market, Tier 2 and 3 companies also make significant contributions, ensuring the Canine Cancer Screening sales remains dynamic and competitive.
The section below covers the industry analysis for the canine cancer screening market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with higher market share through 2034. In East Asia, China is projected to witness a CAGR of 4.1% by 2034.
USA canine cancer screening market is poised to exhibit a CAGR of 3.6% between 2024 and 2034. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
This is a showcase of excellence in technological innovation because the USA has various companies and research institutions working on advanced diagnostic and treatment modalities. Newer technologies such as next-generation sequencing, digital imaging, and liquid biopsies are used widely, making high standards common in early accurate cancer detection in dogs.
USA occupies significant market size due to high pet-owning rates and strong preventive healthcare. There is an increased interest by the owners in investing in thorough health checks in early cancer detection in their pets. This demand is supported by extensive diagnostic services available in the various specialized veterinary clinics and hospitals.
Its strong research and development environment, therefore, consolidates the USA's leading market position. High investment in veterinary oncology research is being made within the country, hence continuously developing with respect to cancer screening technologies and treatment options. Further, stringent regulatory standards ensure that products meet high benchmarks of safety and efficacy, hence contributing to the wide adoption of innovative screening methods.
There is well-established veterinary health care in Germany, followed by the good network of veterinary clinics and diagnostic laboratories equipped with advanced technology. German veterinary professionals have set high standards of care that include the integration of sophisticated diagnostic tools to detect cancers at an early stage. Between 2024 and 2034, Germany is expected to expand at a CAGR of 4.0%.
Research and development also create part of Germany's reason for market leadership. A number of research institutions and companies are situated in the country, with key activities on new developments related to veterinary oncology. This focus on innovation has led to new diagnostic methods, such as molecular diagnostics and advanced imaging technologies, which further increase the accuracy and effectiveness of tumor screening for canines.
In addition, there is a well-structured regulatory framework in Germany that guarantees safety and efficacy for veterinary products. A high level of regulatory stringency helps to support the introduction and wide diffusion of diagnostic tools and high-quality treatment.
Germany has a well-established system of veterinary care, with much attention directed toward the provision of quality animal health services. The emphasis on comprehensive care lends support to the demand for dietary supplements aimed at improving animal health.
India’s canine cancer screening market is poised to exhibit a CAGR of 3.4% between 2024 and 2034. Currently, it holds the highest share in the Asia Pacific market, and the trend is expected to continue during the forecast period.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| USA | 3.6% |
| Germany | 4.0% |
| China | 4.1% |
| France | 3.6% |
| India | 3.4% |
| Spain | 4.2% |
| UK | 4.4% |
| South Korea | 2.5% |
Certain key reasons make India the next-door opportunity for growth in the canine cancer screening market: the continuous growth of the pet population, along with rising awareness about animal health, provides fertile grounds for the growth of cancer screening in veterinary applications. With an increase in pet ownership, demand for advanced diagnostic tools and preventive care also increases, such as cancer screening.
One of the main market features in India is that there are a great many small-scale producers who can provide diagnostic solutions at relatively low costs. These small-scale manufacturers are beginning to make affordable options available to the price-sensitive segments within the pet care industry, adding to the diversity of the market landscape. The ability of these companies to adapt to local needs and offer competitive pricing makes advanced cancer screening more accessible to a broader range of pet owners.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section contains information about the leading segments in the industry. By technology, the next-generation sequencing (NGS) segment holds the highest market share of 27.4% in 2024.
| By Technology | Next-Generation Sequencing (NGS) |
|---|---|
| Value Share (2024) | 27.4% |
Next-Generation Sequencing, has drastically changed the means of dog cancer detection and diagnosis. The ability of NGS to provide detailed insights into the genetic makeup of tumors makes it a preferred choice for both diagnostics and research. NGS provides a high precision due to comprehensive genomic analysis, thereby enabling veterinarians to quickly identify genetic mutations and alterations related to various types of cancer. Early detection helps improve the treatment outcome and survival of canine patients.
By identifying specific biomarkers and genetic mutations, NGS facilitates personalized treatment plans, which are increasingly becoming the standard in veterinary oncology. This technology’s high accuracy and the depth of information it provides surpass traditional diagnostic methods, making it the gold standard in the industry.
Moreover, the demand for precision medicine in veterinary treatment has been changing, thereby continuing to increase the adoption rates of NGS. While pet owners are gaining awareness of the benefits of cancer diagnosis early and accurately, the demand for NGS-based screening is rocketing.
| By Test Type | Liquid Biopsy (Blood-based tests) |
|---|---|
| Value Share (2024) | 36.7% |
Non-invasive liquid biopsy, especially blood-based tests, has become one of the dominant forces in the canine cancer screening market due to the very accurate and facile way it detects cancer early. In contrast to traditional methods of tissue biopsy, which may be invasive and stressful for dogs, liquid biopsy enables the detection of genetic mutations and biomarkers related to cancer directly from a simple blood sample. This significantly simplifies the testing process, and this can be easily made available for routine monitoring and early detection.
Liquid biopsies taken from blood are especially for detecting ctDNA-small fragments of circulating tumor DNA that carry crucial information about the presence and type of cancer in an organism. This technology enables veterinarians to detect cancer at an earlier stage of the disease, when clinical symptoms are not yet apparent, which is very important for improving treatment outcomes and survival rates.
Liquid biopsy also finds its increasing adoption in the process of screening various types of cancers among canines, simply due to increasing awareness about the benefits of early diagnosis of cancer among the pet owners.
The market players are using strategies to stay competitive, such as product differentiation through innovative formulations, strategic partnerships with healthcare providers for distribution. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in Canine Cancer Screening Market:
In terms of test type, the industry is segregated into liquid biopsy (blood-based tests), tissue biopsy, genomic testing and biomarker tests.
In terms of technology, the industry is segregated into next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), flow cytometry and in situ hybridization.
In terms of cancer, the industry is segregated into lymphoma, mast cell tumors, osteosarcoma and hemangiosarcoma.
In terms of end user, the industry is segregated into veterinary clinics, veterinary hospitals, diagnostic laboratories, academic & research institutes, pet owners (home-based testing kits).
Key countries of North America, Latin America, Western Europe, Eastern, South Asia, East Asia and Middle East and Africa (MEA) have been covered in the report.
The global canine cancer screening market is projected to witness CAGR of 4.1% between 2024 and 2034.
The global Canine Cancer Screening industry stood at USD 1,342.0 million in 2023.
The global Canine Cancer Screening Market is anticipated to reach USD 2,087.9 million by 2034 end.
UK is set to record the highest CAGR of 4.4% in the assessment period.
The key players operating in the global canine cancer screening market include IDEXX, Mars Pedtcare, Zoetis, PetDx, Molecular Diagnostics (MDxHealth), Biomérieux SA, OncoK9, Antech Diagnostics, VolitionRx Limited, Oncotect and Heska Corporation.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-Economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand (Value in USD) and Volume (Units) Analysis 2018 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market - Pricing Analysis 6. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034 6.1. By Test 6.2. By Technology 6.3. By Cancer 6.4. By End User 6.5. By Region 7. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Test 7.1. Liquid Biopsy (Blood-based tests) 7.2. Tissue Biopsy 7.3. Genomic Testing 7.4. Biomarker Tests 8. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Technology 8.1. Next-Generation Sequencing (NGS) 8.2. Polymerase Chain Reaction (PCR) 8.3. Immunohistochemistry (IHC) 8.4. Flow Cytometry 8.5. In Situ Hybridization 9. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, Cancer 9.1. Lymphoma 9.2. Mast Cell Tumours 9.3. Osteosarcoma 9.4. Hemangiosarcoma 10. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By End User 10.1. Veterinary Clinics 10.2. Veterinary Hospitals 10.3. Diagnostic Laboratories 10.4. Academic & Research Institutes 10.5. Pet Owners (Home-based Testing Kits 11. Global Market Analysis 2018 to 2023 and Forecast 2024 to 2034, By Region 11.1. North America 11.2. Latin America 11.3. Western Europe 11.4. Eastern Europe 11.5. South Asia & Pacific 11.6. East Asia 11.7. Middle East & Africa 12. North America Sales Analysis 2018 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales Analysis 2018 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Western Europe Sales Analysis 2018 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Eastern Europe Sales Analysis 2018 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. South Asia & Pacific Sales Analysis 2018 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. East Asia Sales Analysis 2018 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East and Africa Sales Analysis 2018 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 by Test, by Technology, by Cancer and by End User Form for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. IDEXX 21.2. Mars Pedtcare 21.3. Zoetis 21.4. PetDx 21.5. Molecular Diagnostics (MDxHealth) 21.6. Biomérieux SA 21.7. OncoK9 21.8. Antech Diagnostics 21.9. VolitionRx Limited 21.10. Oncotect 21.11. Heska Corporation
Explore Healthcare Insights
View Reports
Canine Cancer Screening Market
